GFM
IBRX icon

GF Fund Management’s ImmunityBio IBRX Stock Holding History

GF Fund Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$190K Sell
21,749
-371
-2% -$2.81K ﹤0.01% 282
2026
Q1 		$170K Buy
22,120
+2,765
+14% +$18.9K ﹤0.01% 298
2025
Q4 		$38.3K Sell
19,355
-982
-5% -$2.23K ﹤0.01% 429
2025
Q3 		$50K Buy
20,337
+2,494
+14% +$6.42K ﹤0.01% 395
2025
Q2 		$47.1K Hold
17,843
– – ﹤0.01% 419
2025
Q1 		$53.7K Buy
17,843
+3,211
+22% +$9.73K ﹤0.01% 414
2024
Q4 		$37.5K Buy
+14,632
New +$61K ﹤0.01% 418

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GF Fund Management's IBRX Position: Q2 2026 in Review

GF Fund Management reduced its ImmunityBio (IBRX) stake by 1.7% in Q2 2026, selling an estimated $2.81K and leaving 21,749 shares worth $190K. The position accounts for ﹤0.01% of the portfolio, ranked #282.

GF Fund Management first reported a position in IBRX in Q4 2024 and has held it in 7 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • GF Fund Management held 21,749 shares of ImmunityBio worth $190K as of Q2 2026.
  • GF Fund Management sold 371 ImmunityBio shares in Q2 2026, an estimated $2.81K.
  • ImmunityBio made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #282 holding.
  • GF Fund Management first reported a position in ImmunityBio in Q4 2024 and has held it in 7 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.